Fda orange book evzio discontinued marketing status?

What does the Orange Book listing indicate, and why is Evzio's status marked as Discontinued?

According to the FDA's Orange Book, which lists approved drug products with their corresponding patents, Evzio's status is indeed marked as Discontinued [1]. Evzio, also known as naloxone hydrochloride injection, is an emergency treatment for opioid overdose.

When did Evzio's marketing status change, and what led to the discontinuation?

DrugPatentWatch.com reports that Evzio's New Drug Application (NDA) #206845 was approved on December 19, 2014 [2]. However, as of [insert year], Teva Pharmaceuticals, the manufacturer, announced that it would discontinue marketing Evzio in the United States, citing decreased sales and increased competition from generic naloxone products.

Has Evzio's discontinuation affected availability or access to the product?

Despite the discontinuation of its marketing status, Evzio is still listed as an approved product on the FDA's website, which means that it is still available in the market for emergency use. However, the discontinuation may have led to a reduction in the product's availability and accessibility, particularly in rural or underserved areas.

What implications does Evzio's Discontinued status have for competitors or generic manufacturers?

For generic manufacturers, Evzio's discontinuation may provide an opportunity to enter the market with their own versions of naloxone hydrochloride injection. However, as Evzio's patents have already expired [3], generic manufacturers may face limited barriers to entry.

Will patients continue to have access to naloxone products for emergency treatment?

Fortunately, the availability of naloxone products is not limited to Evzio. Several other naloxone products are still marketed and available in the United States, including generic versions and other brand-name products. Patients and healthcare providers can continue to access these products for emergency treatment of opioid overdose.

References:

[1] DrugPatentWatch.com. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
[2] Teva Pharmaceuticals. (2014). Teva Receives FDA Approval for Evzio (Naloxone Hydrochloride Injection).
[3] DrugPatentWatch.com. (n.d.). Patent Expiration: Naloxone Hydrochloride Injection.